| Oct 28, 2009
| 4:32 PM
About this time last year, we were reporting on the failure of several investigational weight-loss medications. They included Sanofi-Aventis' rimonabant as well as two other drugs that aimed to work by blocking cannabinoid receptors in the brain. However, one
| Feb 25, 2014
| 9:27 AM
Feb 25 (Reuters) - Vivus Inc's silence on its
strategy to boost sales of obesity drug Qsymia has increased
doubts about whether the pill will reach its full commercial
Shares of the company, which reported quarterly results on
| Feb 20, 2014
| 7:09 AM
Feb 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets
on several U.S.-listed companies, including Eli Lilly, Facebook, HomeAway and Tesla Motors , on
* Arris Group Inc : RBC, UBS, Needham,...
| Oct 4, 2009
| 12:40 PM
Several San Diego biotechnology firms that were on the brink of bankruptcy in the depths of the recession this spring are finding their lifeblood -- cash -- easier to come by, it was reported today.
Adventrx Pharmaceuticals, which had whittled its...
| Oct 25, 2010
The FDA has told the makers of the proposed weight-loss drug Lorcaserin that it will not at this time approve the marketing of the medication, citing concerns about its marginal effectiveness and about cancers that occurred at higher-than-usual rates...